

# 5-HT<sub>7</sub> receptor modulates GABAergic transmission in the rat dorsal raphe nucleus and controls cortical release of serotonin

Magdalena Kusek<sup>1</sup>, Joanna Sowa<sup>1</sup>, Katarzyna Kamińska<sup>2</sup>, Krystyna Golembiowska<sup>2</sup>, Krzysztof Tokarski<sup>1\*</sup> and Grzegorz Hess<sup>1,3</sup>

<sup>1</sup> Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, <sup>2</sup> Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, <sup>3</sup> Institute of Zoology, Jagiellonian University, Krakow, Poland

## OPEN ACCESS

### Edited by:

Tycho M. Hoogland,  
Netherlands Institute for  
Neuroscience, Netherlands

### Reviewed by:

Lynn G. Kirby,  
University of Pennsylvania, USA  
Andreas Draguhn,  
University of Heidelberg, Germany

### \*Correspondence:

Krzysztof Tokarski,  
Department of Physiology, Institute  
of Pharmacology, Polish Academy  
of Sciences, Smetna 12,  
31-343 Krakow, Poland  
ktok@if-pan.krakow.pl

**Received:** 29 May 2015

**Accepted:** 05 August 2015

**Published:** 18 August 2015

### Citation:

Kusek M, Sowa J, Kamińska K,  
Golembiowska K, Tokarski K and  
Hess G (2015) 5-HT<sub>7</sub> receptor  
modulates GABAergic transmission  
in the rat dorsal raphe nucleus and  
controls cortical release of serotonin.  
*Front. Cell. Neurosci.* 9:324.  
doi: 10.3389/fncel.2015.00324

The 5-HT<sub>7</sub> receptor is one of the several serotonin (5-HT) receptor subtypes that are expressed in the dorsal raphe nucleus (DRN). Some earlier findings suggested that 5-HT<sub>7</sub> receptors in the DRN were localized on GABAergic interneurons modulating the activity of 5-HT projection neurons. The aim of the present study was to find out how the 5-HT<sub>7</sub> receptor modulates the GABAergic synaptic input to putative 5-HT DRN neurons, and whether blockade of the 5-HT<sub>7</sub> receptor would affect the release of 5-HT in the target structure. Male Wistar rats with microdialysis probes implanted in the prefrontal cortex (PFC) received injections of the 5-HT<sub>7</sub> receptor antagonist (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine hydrochloride (SB 269970), which induced an increase in the levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA) in the PFC. In another set of experiments whole-cell recordings from presumed projection neurons were carried out using DRN slices. SB 269970 application resulted in depolarization and in an increase in the firing frequency of the cells. In order to activate 5-HT<sub>7</sub> receptors, 5-carboxamidotryptamine (5-CT) was applied in the presence of N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY100635). Hyperpolarization of cells and a decrease in the firing frequency were observed after activation of the 5-HT<sub>7</sub> receptor. Blockade of 5-HT<sub>7</sub> receptors caused a decrease in the mean frequency of spontaneous inhibitory postsynaptic currents (sIPSCs), while its activation induced an increase. The mechanism of these effects appears to involve tonically-active 5-HT<sub>7</sub> receptors modulating firing and/or GABA release from inhibitory interneurons which regulate the activity of DRN serotonergic projection neurons.

**Keywords:** brain slices, HPLC, microdialysis, prefrontal cortex, whole-cell recording

**Abbreviations:** 5-CT, 5-carboxamidotryptamine; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine, serotonin; ACSF, artificial cerebrospinal fluid; DRN, dorsal raphe nucleus; SB 269970, (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl] pyrrolidine hydrochloride; sIPSC, spontaneous inhibitory postsynaptic current; WAY 100635, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide.

## Introduction

The dorsal raphe nucleus (DRN) is the main source of widespread serotonin (5-hydroxytryptamine, 5-HT) projections to the forebrain, which regulate the activity of neuronal circuits involved in a spectrum of functions including emotional states, sleep, motivation and aggression (reviewed in Celada et al., 2013; Paul and Lowry, 2013). DRN 5-HT projection neurons have been thoroughly studied (reviewed in Aghajanian et al., 1990; Gaspar and Lillesaar, 2012; Andrade and Haj-Dahmane, 2013). These cells exhibit *in vivo* a regular, slow activity pattern and fire broad (2–3 ms) action potentials which are generated by a combination of voltage-dependent sodium and calcium conductances (Penington et al., 1991; Beck et al., 2004). DRN also contains numerous nonserotonergic neurons which release glutamate, GABA, as well as dopamine and peptide transmitters (Kirby et al., 2003; reviewed in Liu et al., 2000; Commons, 2009; Soiza-Reilly and Commons, 2014). Some of these cells are local interneurons (Commons, 2009; Calizo et al., 2011); however, recent work has demonstrated that many DRN projection neurons are glutamatergic or GABAergic (Jackson et al., 2009; Bang and Commons, 2012). Moreover, subsets of DRN 5-HT neurons coexpress glutamate or GABA (Commons, 2009; Shikanai et al., 2012).

The activity of DRN neurons is modulated by the locally released 5-HT (Hernandez-Lopez et al., 2013). Serotonin receptors in the central nervous system have been classified as members of seven families and at least 15 subtypes on the basis of their pharmacological properties, their coupling to intracellular signaling cascades and the protein structure (Hoyer et al., 2002). DRN 5-HT neurons have been found to express 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub> and possibly, 5-HT<sub>2</sub> autoreceptors (McDevitt and Neumaier, 2011). Another receptor, abundant in the DRN, is the 5-HT<sub>7</sub> one (Roberts et al., 2001). Beside the DRN, high levels of 5-HT<sub>7</sub> receptor mRNA and protein are present in the thalamus, hippocampus, frontal cortex and hypothalamus (reviewed in Hedlund and Sutcliffe, 2004). This receptor stimulates adenylyl cyclase via G<sub>αs</sub> proteins and is also coupled to the G<sub>12</sub> protein; and moreover, it activates small GTPases of the Rho family (reviewed in Gellynck et al., 2013; Guseva et al., 2014). Activation of the 5-HT<sub>7</sub> receptor increases the excitability of the neuron that expresses it (Bacon and Beck, 2000; Bickmeyer et al., 2002; Tokarski et al., 2003). A considerable body of experimental evidence indicates that the 5-HT<sub>7</sub> receptor may be involved in the etiology of mental illnesses (reviewed in Hedlund, 2009; Ciranna and Catania, 2014). Also, recent research has suggested that the antagonists of this receptor may constitute a new class of antidepressant drugs with a faster therapeutic action than that of the currently used drugs (Mnie-Filali et al., 2011; reviewed in Tokarski et al., 2012).

It has been reported that administration of the 5-HT<sub>7</sub> receptor agonist AS19 results in a reduction in the firing rate of rat DRN 5-HT cells *in vivo* (Mnie-Filali et al., 2011). On the other hand, blockade of the 5-HT<sub>7</sub> receptor by the selective antagonist (2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine hydrochloride (SB

269970; Hagan et al., 2000) has been shown to increase the extracellular level of 5-HT in the prefrontal cortex (PFC; Wesołowska and Kowalska, 2008; but see Bonaventure et al., 2007). These findings are consistent with the hypothesis that 5-HT<sub>7</sub> receptors in the DRN are not localized on 5-HT cells, but rather on local GABAergic interneurons which modulate the activity of 5-HT projection neurons (Harsing, 2006). The 5-HT<sub>7</sub> receptor-dependent modulation of inhibitory influence on DRN projection neurons is has not yet been explored (Liu et al., 2000; Gocho et al., 2013; Weissbourd et al., 2014; Commons, 2015). Therefore, in the present study we aimed at determining how the 5-HT<sub>7</sub> receptor activation and blockade modulate the GABAergic synaptic input to electrophysiologically identified, broad action potential-exhibiting DRN neurons in a slice preparation. We have also investigated, whether blockade of the 5-HT<sub>7</sub> receptor would influence the extracellular level of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in the PFC *in vivo*.

## Materials and Methods

### Animals

All experimental procedures were approved by the Local Ethics Committee for Animal Experiments at the Institute of Pharmacology, Polish Academy of Sciences, and were carried out in accordance with the European Community guidelines for the use of experimental animals and the national law. Male Wistar rats (Charles River, Germany) were housed in groups in standard laboratory cages and kept in a constant temperature- and humidity-controlled colony room (21 ± 2°C) on a 12 h light/dark cycle (the light on at 07:00, off at 19:00). Commercial food and tap water were available *ad libitum*.

### Microdialysis

Rats (250–300 g) were anaesthetized with ketamine (75 mg/kg IM) and xylazine (10 mg/kg IM) and put in a stereotaxic apparatus (David Kopf Instruments, USA). The scalp was retracted and holes were drilled through the skull to insert vertical microdialysis probes into the PFC (2.9 mm anterior from the bregma, 0.8 mm lateral from the sagittal suture and –4.5 ventral from the dural surface; Paxinos and Watson, 1998). The microdialysis probes were constructed by inserting two fused silica tubes (30 and 35 mm long, 150 μm outer diameter (o.d.); Polymicro Technologies Inc., USA) into a microdialysis fiber (220 μm o.d.; AN69, Hospal, Italy). The tube assembly was placed in a stainless steel cannula (22 gauge, 10 mm) making the shaft of the probe. Parts of inlet and outlet tubes were individually placed inside the polyethylene PE-10 tubing and glued for protection. The free end of the dialysis fiber was sealed, and its 3 mm exposed length was used for a dialysis in the PFC. One day after probe implantation, the inlet of the dialysis probe was connected to a syringe pump (BAS, USA) which delivered an artificial cerebrospinal fluid (ACSF) composed of (in mM): NaCl (145), KCl (4), MgCl<sub>2</sub> (1), CaCl<sub>2</sub> (2.2); pH = 7.4 at a flow rate of 2.0 μl/min. After a 2 h rinsing period, baseline

samples (3–4) were collected every 20 min. SB 269970 (1.25 or 2.5 mg/kg) was dissolved in a 0.9% saline and injected in a volume of 4 ml/kg IP. Samples were collected every 20 min for 4 h. At the end of the experiment the rats were sacrificed and their brains were histologically examined to validate the correct probe placement.

5-HT and 5-HIAA levels were analyzed by HPLC with a coulochemical detection. Chromatography was performed using the Ultimate 3000 System (Dionex, USA), the coulochemical detector Coulochem III (model 5300, ESA, USA) with the 5020 guard cell, the 5014B microdialysis cell and the Hypersil Gold-C<sub>18</sub> analytical column (3 × 100 mm). The mobile phase was composed of 0.05 M potassium phosphate buffer adjusted to pH = 3.9, 0.5 mM EDTA, 13 mg/L 1-octanesulfonic acid sodium salt, a 3.1% methanol and a 0.93% acetonitrile. The flow rate during the analysis was 0.7 ml/min. The applied potential of a guard cell was +600 mV, while those of a microdialysis cell were E<sub>1</sub> = -50 mV and E<sub>2</sub> = +300 mV and a sensitivity was set at 50 nA/V. The chromatographic data were processed by the Chromleon v. 6.80 (Dionex, USA) software run on a PC computer. The values were not corrected for an *in vitro* probe recovery which was ca. 15%.

### Slice Preparation and Incubation

Rats (150 g) were decapitated under isoflurane anesthesia (Aerrane, Baxter, UK), their brains were quickly removed and placed in an ice-cold modified ACSF containing (in mM): NaCl (130), KCl (5), CaCl<sub>2</sub> (2.5), MgSO<sub>4</sub> (1.3), KH<sub>2</sub>PO<sub>4</sub> (1.25), NaHCO<sub>3</sub> (26) and D-glucose (10), bubbled with the mixture of 95% O<sub>2</sub>-5% CO<sub>2</sub>. Coronal midbrain slices containing the DRN (300 μm thick) were cut using a vibrating microtome (VT1000, Leica, Germany). Two slices were obtained from one animal. Slices were then stored submerged in ACSF at 30 ± 0.5°C.

An individual slice was placed in the recording chamber, being superfused at 3 ml/min with warm (32 ± 0.5°C), modified ACSF of the following composition (in mM): NaCl (132), KCl (2), KH<sub>2</sub>PO<sub>4</sub> (1.25), NaHCO<sub>3</sub> (26), MgSO<sub>4</sub> (1.3), CaCl<sub>2</sub> (2.5), D-glucose (10), bubbled with 95% O<sub>2</sub>-5% CO<sub>2</sub>. Neurons were visualized using the Axioskop 2 (Zeiss, Germany) upright microscope with the Nomarski optics, a 40× water immersion lens and an infrared camera (Tokarski et al., 2007).

### Analysis of Intrinsic Excitability and Inhibitory Postsynaptic Currents

Patch pipettes were pulled from borosilicate glass capillaries using the Sutter Instrument P97 puller. The pipette solution contained (in mM): K-gluconate (130), NaCl (5), CaCl<sub>2</sub> (0.3), MgCl<sub>2</sub> (2), HEPES (10), Na<sub>2</sub>-ATP (5), Na-GTP (0.4) and EGTA (1). Osmolarity and pH were adjusted to 290 mOsm and 7.2, respectively. Pipettes had an open tip resistance of approximately 6 MΩ.

Whole-cell recordings were obtained from presumed 5-HT DRN neurons which were identified on the basis of their response to hyper- and depolarizing current pulses (Figures 1A,B; cf. Galindo-Charles et al., 2008). Cells were sampled from the dorsal part of the midline region of the DRN. Signals were recorded using the SEC 05LX amplifier (NPI, Germany), filtered at 2

kHz and digitized at 20 kHz using the Digidata 1440 interface and pClamp 10 software (Molecular Devices, USA). An input-output relationship was assessed in the current-clamp mode using hyper- and depolarizing current pulses (500 ms). To assess the relationship between the injected current and the spiking rate (gain) depolarizing current was increased in 20 pA steps, delivered every 2 s. The width of the action potential was measured at the threshold, which was determined according to Henze and Buzsáki (2001).

To record spontaneous inhibitory postsynaptic currents (sIPSCs), neurons were voltage-clamped at 0 mV (Tokarski et al., 2007). After 15 min of the stabilization period the baseline sIPSCs activity was recorded for 4 min. To block the 5-HT<sub>7</sub> receptor, its selective antagonist SB 269970 (Hagan et al., 2000) was then added to the ACSF and after next 15 min of stabilization sIPSCs were recorded for 4 min. In the experiments involving activation of the 5-HT<sub>7</sub> receptor slices were incubated in the ACSF supplemented with N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY100635, 2 μM, a selective 5-HT<sub>1A</sub> antagonist; Munday et al., 1996; Tokarski et al., 2003). After obtaining whole-cell configuration, the stabilization period (15 min) and the baseline recording (4 min), 200 nM 5-CT (a nonselective agonist) was added to the ACSF. After the following 15 min of stabilization sIPSCs were recorded for 4 min. Data were accepted for analysis when the access resistance ranged between 15 and 18 MΩ and it was stable during recordings. The recordings were inspected off-line using the Mini Analysis software (Synaptosoft) and individual synaptic events were selected manually for further analysis.



### Statistical Analysis

The results are expressed as the mean ± SEM unless otherwise noted. The statistical significance of the microdialysis data was calculated using repeated-measures ANOVA, followed by Tukey's *post hoc* test, if applicable. Statistical analyses of the electrophysiological data were carried out using paired Student's *t*-tests, Wilcoxon signed-rank test and Kolmogorov-Smirnov test, where applicable.

## Results

### The 5-HT<sub>7</sub> Receptor Antagonist SB 269970 Induces 5-HT Release in the Prefrontal Cortex *In Vivo*

The basal concentrations of 5-HT in dialysates from the PFC were 1.29 ± 0.19 pg/10 μl, 1.18 ± 0.16 pg/10 μl and 0.91 ± 0.09 pg/10 μl in the control group, in rats receiving 1.25 mg/kg SB 269970 and in rats receiving 2.5 mg/kg SB 269970, respectively. Those differences were not statistically significant. Injections of SB 269970 increased the extracellular level of 5-HT, which reached approximately 300% of the basal level at the higher dose of the drug during the first hour after its injection (Figure 2A). No difference in 5-HT level increase between both doses of SB 269970 was observed between 90–240 min after the administration of the drug. A significant



effect of treatment with SB 269970 on 5-HT level was observed (ANOVA,  $F_{(2,17)} = 12.18$ ,  $p < 0.0005$ ). There was no effect of time (ANOVA,  $F_{(7,119)} = 1.16$ ,  $p < 0.33$ ) and there was no interaction between both factors (ANOVA,  $F_{(14,119)} = 1.59$ ,  $p < 0.09$ ).

The basal concentrations of 5-HIAA were  $677 \pm 22$  pg/10  $\mu$ l,  $600 \pm 37$  pg/10  $\mu$ l and  $607 \pm 30$  pg/10  $\mu$ l in the control group, in rats receiving 1.25 mg/kg SB 269970 and in rats receiving 2.5 mg/kg SB 269970, respectively. There were no significant differences between the groups. SB 269970 increased the extracellular level of 5-HIAA only at the higher dose with the maximum reaching approximately 138% of the basal level 60 min after administration (Figure 2B). This effect corresponded to an increase in the extracellular level of 5-HT but it occurred about 30 min later. A significant effect of treatment with the drug on 5-HIAA (ANOVA,  $F_{(2,17)} = 7.56$ ,  $p < 0.004$ ), as well as a significant effect of time (ANOVA,  $F_{(7,119)} = 14.73$ ,  $p < 0.0001$ ) and an interaction between both those factors (ANOVA,  $F_{(14,119)} = 8.00$ ,  $p < 0.0001$ ) were observed.

### The 5-HT<sub>7</sub> Receptor Antagonist SB 269970 Enhances Spiking Activity and Reduces the Inhibitory Input to Neurons in DRN Slices

In response to depolarizing current pulses (500 ms), all the cells subjected to the analysis showed adaptation of the firing frequency (Figure 1B<sub>1</sub>). In the case of stronger current pulses (500–600 pA), an average firing frequency reached 12–16 Hz. Their action potentials were broad ( $3.66 \pm 0.06$  ms) and they showed a characteristic inflection during the descending phase of the spike (Figure 1B<sub>2</sub>). The mean input resistance of those cells was  $432.13 \pm 23.55$  M $\Omega$ , and they showed no spontaneous spiking activity at the resting membrane potential ( $-64.5 \pm 3.4$  mV). As illustrated in Figure 1C, presumed non-5-HT DRN neurons exhibited higher firing frequencies (range: 36–42 Hz) and lower input resistance ( $260.12 \pm 20.32$  M $\Omega$ ) than presumed 5-HT cells (cf. Galindo-Charles et al., 2008).


A sample of cells ( $n = 11$ ; 6 animals) was depolarized in the current-clamp mode to either  $-50$  or  $-45$  mV by current injection (15–55 pA) to induce sustained firing (Figure 3A). In order to study the effect of 5-HT<sub>7</sub> receptor blockade on depolarization-induced sustained activity, SB 269970 (2.5  $\mu$ M)

was added to the ACSF, which resulted in further depolarization of the cells by  $4.9 \pm 0.5$  mV ( $n = 11$ ; 6 animals, paired  $t$ -test,  $t = -5.012$ ,  $df = 10$ ,  $p < 0.001$ ; **Figures 3A,B**) and in an increase in the sustained firing frequency up to  $182 \pm 24\%$  of the baseline ( $n = 11$ ; 6 animals, paired  $t$ -test,  $t = -4.418$ ,  $df = 10$ ,  $p = 0.002$ ; **Figure 3C**). The blockade of 5-HT<sub>7</sub> receptors did not modify the excitability of DRN neurons ( $n = 6$ ; 3 animals, paired  $t$ -test,  $t = 0.702$ ,  $df = 5$ ,  $p = 0.514$ ; **Figures 3E,F**). No change in the sustained spiking frequency occurred when the membrane potential was adjusted to the baseline level with a steady current injection ( $n = 9$ ; 5 animals, paired  $t$ -test,  $t = -1.411$ ,  $df = 8$ ,  $p = 0.196$ ; **Figure 3C**). No change in the sustained spiking frequency and no depolarization occurred when SB 269970 (2.5  $\mu$ M) was added to the ACSF supplemented with 10  $\mu$ M bicuculline to block GABA<sub>A</sub> receptors and with 2 mM kynurenic acid to block the excitatory transmission (**Figures 3C,D**;  $n = 5$ ; 3 animals; spiking frequency: paired  $t$ -test,  $t = -1.5$ ,  $df = 4$ ,  $p = 0.208$ ; membrane potential: paired  $t$ -test,  $t = -0.535$ ,  $df = 4$ ,  $p = 0.621$ ).


A separate sample of presumed DRN projection neurons ( $n = 11$ , 6 animals) was voltage-clamped at 0 mV to record spontaneous IPSCs (**Figure 4A**). The mean frequency and mean amplitude ( $\pm$  SEM) of sIPSCs during baseline recordings were  $0.751 \pm 0.084$  Hz and  $26.89 \pm 1.36$  pA, respectively. Addition of SB 269970 (2.5  $\mu$ M) to the ACSF resulted in a decrease in the mean frequency of sIPSCs to  $0.663 \pm 0.0821$  Hz (Wilcoxon signed-rank test,  $p < 0.001$ ; **Figures 4B,C**). The mean amplitude of sIPSCs remained unchanged (Wilcoxon signed-rank test,  $26.66 \pm 1.33$  pA;  $p = 0.07$ ; **Figure 4C**).

### Activation of the 5-HT<sub>7</sub> Receptor Suppresses Spiking Activity and Enhances the Inhibitory Input to Neurons in DRN Slices

A group of cells ( $n = 10$ ; 5 animals) was depolarized in the current-clamp mode by current injection (25–40 pA) to induce sustained firing (**Figure 5A**). To activate the 5-HT<sub>7</sub> receptor, 250 nM 5-CT (a nonselective agonist) was added to the ACSF supplemented with N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexane carboxamide (WAY100635, 2  $\mu$ M, a selective 5-HT<sub>1A</sub> antagonist; Tokarski et al., 2003). Hyperpolarization of the cells by  $4.4 \pm 1.1$  mV ( $n = 10$ ; 5 animals; paired  $t$ -test,  $t = 2.857$ ,  $df = 9$ ,  $p = 0.019$ ; **Figures 5A,B**) and a decrease in the sustained firing frequency to  $76.5 \pm 3.9\%$  of the baseline ( $n = 10$ ; 5 animals, paired  $t$ -test,  $t = 5.432$ ,  $df = 9$ ,  $p = 0.002$ ; **Figure 5C**) were observed. Activation of the 5-HT<sub>7</sub> receptor did not modify the excitability of DRN neurons ( $n = 8$ ; 4 animals; paired  $t$ -test,  $t = 1.09$ ,  $df = 7$ ,  $p = 0.312$ ; **Figures 5E,F**). No change in the sustained spiking frequency occurred when the membrane potential was adjusted to the baseline level with a steady current injection ( $n = 8$ ; 4 animals, paired  $t$ -test,  $t = -1.83$ ,  $df = 7$ ,  $p = 0.11$ ; **Figure 5C**). No change in the sustained spiking frequency and no depolarization occurred when 5-CT (250 nM) was added to the ACSF supplemented with 10 mM bicuculline to block GABA<sub>A</sub> receptors and with 2 mM kynurenic acid to block the excitatory transmission (**Figures 5C,D**;  $n = 5$ ; 3



animals; spiking frequency: paired  $t$ -test,  $t = 1.195$ ,  $df = 4$ ,  $p = 0.298$ ; membrane potential: paired  $t$ -test,  $t = 0.667$ ,  $df = 4$ ,  $p = 0.541$ ).



A separate sample of presumed DRN projection neurons ( $n = 33$ , 17 animals) was voltage-clamped at 0 mV to record sIPSCs (Figure 6A). As shown in Figures 6B,C and Table 1, addition of 5-CT (50–500 nM) to the ACSF resulted in a dose-dependent increase in the mean frequency of sIPSCs.


## Discussion

The results of the present study indicate that blockade of the 5-HT<sub>7</sub> receptor enhances the release and metabolism of 5-HT in the PFC. This effect appears to be mediated by the depolarization and enhanced firing of DRN serotonergic projection neurons, resulting from a decreased inhibitory synaptic input received by the projection cells. In contrast, activation of the 5-HT<sub>7</sub> receptor increases the frequency of spontaneous IPSCs, which results in hyperpolarization and reduced firing of the putative DRN projection cells.

The present results confirm and extend an earlier report that showed that blockade of the 5-HT<sub>7</sub> receptor with low doses of SB 269970 (0.625 and 1.25 mg/kg) resulted in an increase in the level of extracellular 5-HT (Wesołowska and Kowalska, 2008). The effect of a higher dose of SB 269970 (2.5 mg/kg), used in the present study, was more potent, but only during the first hour after the administration. This result points to the activation of mechanisms which do not allow for an excessive tonic release of 5-HT from cortical terminals. An increase in the level of 5-HIAA is consistent with an increased level of

5-HT in the extracellular space. Another study demonstrated that SB 269970 administered in a dose of 10 mg/kg did not increase the extracellular concentration of 5-HT in the rat frontal cortex (Bonaventure et al., 2007). A most likely explanation of such an apparent discrepancy is the way of drug administration: intraperitoneal (Wesołowska and Kowalska, 2008 and our study) vs. subcutaneous (Bonaventure et al., 2007).

All the examined cells showed a low frequency, rhythmic activity after moderate depolarization, broad action potentials, adaptation of the firing frequency during depolarizing steps and an inflection on the descending phase of the spike (cf. Galindo-Charles et al., 2008). Those features were originally considered to be unique to DRN 5-HT neurons (Aghajanian et al., 1990). Later on it was shown that the population of DRN neurons with similar characteristics included non-serotonergic cells; however, there may be subtle differences between these neurons regarding e.g., the timecourse of the afterhyperpolarization (Kirby et al., 2003). We did not carry out an immunohistochemical analysis of the recorded cells, however, other investigators found that 86% of the population of identified, 5-HT-immunoreactive DRN neurons exhibited the inflection on the action potential descending phase and other features characteristic of the cell type we recorded from (Galindo-Charles et al., 2008). Some 5-HT cells also coexpress the GABAergic marker GAD67 (Shikanai et al., 2012), but “pure” DRN GABAergic interneurons, that do not synthesize 5-HT show different activity patterns, including short spikes and considerably higher discharge frequencies



(Galindo-Charles et al., 2008; Shikanai et al., 2012; Gocho et al., 2013). Therefore it may be assumed that a significant fraction of the cells recorded throughout the present study represented 5-HT projection cells. The excitability of these neurons was not directly influenced by the activation or blockade of the 5-HT<sub>7</sub> receptor.

It has been established that DRN neurons receive GABAergic inputs from extrinsic sources, including the hypothalamus, substantia nigra, ventral tegmental area and rostromedial tegmental nucleus (reviewed in Soiza-Reilly and Commons, 2011). Since the axons from these structures are cut during slice preparation, their contribution to the observed effects seems unlikely.

5-HT had previously been shown to induce a concentration-dependent increase in the frequency of sIPSCs recorded from the putative serotonergic neurons in DRN slices (Liu et al., 2000). The latter effect was shown to be mediated by local GABAergic interneurons, since it was blocked by the inhibitor of voltage-gated sodium channels tetrodotoxin. The stimulatory effect of 5-HT on GABAergic interneurons was attributed to the activation of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors; however, even high concentrations of the antagonist of those receptors did not completely block the effects of 5-HT application (Liu et al., 2000; Gocho et al., 2013).


To activate the 5-HT<sub>7</sub> receptor we have applied a nonselective agonist, 5-CT, in the presence of WAY100636, a selective antagonist of the 5-HT<sub>1A</sub> receptor (Mundey et al., 1996). 5-CT has been reported to be an agonist of 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub> and 5-HT<sub>7</sub> receptors. However, the affinity of 5-CT to the 5-HT<sub>7</sub> receptor is one order of magnitude higher than to the 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors.<sup>1</sup> Moreover, activation of the 5-HT<sub>1B</sub> receptor has been reported to increase the firing of DRN 5-HT neurons via a reduction of the inhibitory inputs (Adell et al., 2001). Thus, the effects of 5-CT observed in the present study (increased sIPSCs frequency, hyperpolarization and reduced firing of presumable 5-HT cells) is consistent with the activation of the 5-HT<sub>7</sub> receptor located on GABAergic interneurons. This conclusion is supported by the observation that blockade of the 5-HT<sub>7</sub> receptor induces opposite phenomena. The observed effects of application of the 5-HT<sub>7</sub> receptor antagonist indicate that the receptors are tonically active most likely due to locally released 5-HT. We showed previously that activation of 5-HT<sub>7</sub> receptors resulted in the enhancement of GABAergic transmission in the hippocampal CA1 area, at least partially via 5-HT<sub>7</sub> receptors located on inhibitory interneurons (Tokarski et al., 2011).

The 5-HT<sub>7</sub> receptor is implicated in a wide range of pathological processes; in particular, its selective blockade has been shown to induce antidepressant-like effects in animal models (reviewed in Ciranna and Catania, 2014; Nikiforuk, 2015). The above data point to a plausible cellular mechanism of the antidepressant action of 5-HT<sub>7</sub> receptor antagonists.

## Author Contributions

GH, KT and KG conceived and designed the experiments. MK, JS and KK performed the experiments. MK, JS, KG, KK, KT and GH analyzed and interpreted the obtained data. MK, JS, KG, KT and GH wrote the paper. KK helped with the manuscript preparation. MK, JS, KK, KG, KT and GH granted a final approval of the version of the paper to be published and agreed to be accountable for all aspects of the work.

<sup>1</sup><http://pdsp.med.unc.edu/kidb.php>



**TABLE 1 | The effect of 5-CT on spontaneous IPSCs.**

5-CT concentration (nM)	Mean control frequency (Hz)	Mean frequency in 5-CT (Hz)	Mean control amplitude (pA)	Mean amplitude in 5-CT (pA)	Number of cells
50	0.72 $\pm$ 0.15	0.69 $\pm$ 0.16	26.90 $\pm$ 1.90	26.53 $\pm$ 1.93	6
150	0.60 $\pm$ 0.14	0.75 $\pm$ 0.15*	28.22 $\pm$ 1.37	28.56 $\pm$ 1.41	13
250	0.64 $\pm$ 0.15	1.03 $\pm$ 0.17*	24.23 $\pm$ 1.56	24.34 $\pm$ 1.52	8
500	0.52 $\pm$ 0.07	1.00 $\pm$ 0.11*	28.91 $\pm$ 1.76	29.61 $\pm$ 2.30	6

Data were acquired before (control) and 15 min after addition of 5-CT (in the presence of 2  $\mu$ M WAY100635) to the ACSF. \* $p < 0.005$ . Wilcoxon signed-rank test.

## Acknowledgments

Supported by the grant DEC-2013/11/B/NZ4/04743, financed by the National Science Center, Poland, and by statutory funds

from the Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland. Magdalena Kusek and Joanna Sowa are holders of KNOW scholarships sponsored by the Ministry of Science and Higher Education, Poland.

## References

- Adell, A., Celada, P., and Artigas, F. (2001). The role of 5-HT<sub>1B</sub> receptors in the regulation of serotonin cell firing and release in the rat brain. *J. Neurochem.* 79, 172–182. doi: 10.1046/j.1471-4159.2001.00550.x
- Aghajanian, G. K., Sprouse, J. S., Sheldon, P., and Rasmussen, K. (1990). Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. *Ann. N Y Acad. Sci.* 600, 93–103. doi: 10.1111/j.1749-6632.1990.tb16875.x
- Andrade, R., and Haj-Dahmane, S. (2013). Serotonin neuron diversity in the dorsal raphe. *ACS Chem. Neurosci.* 4, 22–25. doi: 10.1021/cn300224n
- Bacon, W. L., and Beck, S. G. (2000). 5-Hydroxytryptamine<sub>7</sub> receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. *J. Pharmacol. Exp. Ther.* 294, 672–679.
- Bang, S. J., and Commons, K. G. (2012). Forebrain GABAergic projections from the dorsal raphe nucleus identified by using GAD67-GFP knock-in mice. *J. Comp. Neurol.* 520, 4157–4167. doi: 10.1002/cne.23146
- Beck, S. G., Pan, Y. Z., Akanwa, A. C., and Kirby, L. G. (2004). Median and dorsal raphe neurons are not electrophysiologically identical. *J. Neurophysiol.* 91, 994–1005. doi: 10.1152/jn.00744.2003
- Bickmeyer, U., Heine, M., Manzke, T., and Richter, D. W. (2002). Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. *Eur. J. Neurosci.* 16, 209–218. doi: 10.1046/j.1460-9568.2002.02072.x
- Bonaventure, P., Kelly, L., Aluisio, L., Shelton, J., Lord, B., Galici, R., et al. (2007). Selective blockade of 5-hydroxytryptamine (5-HT)<sub>7</sub> receptors enhances

- 5-HT transmission, antidepressant-like behavior and rapid eye movement sleep suppression induced by citalopram in rodents. *J. Pharmacol. Exp. Ther.* 321, 690–698. doi: 10.1124/jpet.107.119404
- Calizo, L. H., Akanwa, A., Ma, X., Pan, Y. Z., Lemos, J. C., Craige, C., et al. (2011). Raphe serotonin neurons are not homogenous: electrophysiological, morphological and neurochemical evidence. *Neuropharmacology* 61, 524–543. doi: 10.1016/j.neuropharm.2011.04.008
- Celada, P., Puig, M. V., and Artigas, F. (2013). Serotonin modulation of cortical neurons and networks. *Front. Integr. Neurosci.* 7:25. doi: 10.3389/fnint.2013.00025
- Ciranna, L., and Catania, M. V. (2014). 5-HT<sub>7</sub> receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders. *Front. Cell. Neurosci.* 8:250. doi: 10.3389/fncel.2014.00250
- Commons, K. G. (2009). Locally collateralizing glutamate neurons in the dorsal raphe nucleus responsive to substance P contain vesicular glutamate transporter 3 (VGLUT3). *J. Chem. Neuroanat.* 38, 273–281. doi: 10.1016/j.jchemneu.2009.05.005
- Commons, K. G. (2015). Two major network domains within the dorsal raphe nucleus. *J. Comp. Neurol.* 523, 1488–1504. doi: 10.1002/cne.23748
- Galindo-Charles, L., Hernandez-Lopez, S., Galarraga, E., Tapia, D., Bargas, J., Garduño, J., et al. (2008). Serotonergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. *Synapse* 62, 601–615. doi: 10.1002/syn.20526
- Gaspar, P., and Lillesaar, C. (2012). Probing the diversity of serotonin neurons. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 367, 2382–2394. doi: 10.1098/rstb.2011.0378
- Gellynck, E., Heynck, K., Andressen, K. W., Haegeman, G., Levy, F. O., Vanhoenacker, P., et al. (2013). The serotonin 5-HT<sub>7</sub> receptors: two decades of research. *Exp. Brain Res.* 230, 555–568. doi: 10.1007/s00221-013-3694-y
- Gocho, Y., Sakai, A., Yanagawa, Y., Suzuki, H., and Saitow, F. (2013). Electrophysiological and pharmacological properties of GABAergic cells in the dorsal raphe nucleus. *J. Physiol. Sci.* 63, 147–154. doi: 10.1007/s12576-012-0250-7
- Guseva, D., Wirth, A., and Ponimaskin, E. (2014). Cellular mechanisms of the 5-HT<sub>7</sub> receptor-mediated signaling. *Front. Behav. Neurosci.* 8:306. doi: 10.3389/fnbeh.2014.00306
- Hagan, J. J., Price, G. W., Jeffrey, P., Deeks, N. J., Stean, T., Piper, D., et al. (2000). Characterization of SB-269970-A, a selective 5-HT<sub>7</sub> receptor antagonist. *Br. J. Pharmacol.* 130, 539–548. doi: 10.1038/sj.bjp.0703357
- Harsing, L. G. Jr. (2006). The pharmacology of the neurochemical transmission in the midbrain raphe nuclei of the rat. *Curr. Neuropharmacol.* 4, 313–339. doi: 10.2174/157015906778520764
- Hedlund, P. B. (2009). The 5-HT<sub>7</sub> receptor and disorders of the nervous system: an overview. *Psychopharmacology (Berl)* 206, 345–354. doi: 10.1007/s00213-009-1626-0
- Hedlund, P. B., and Sutcliffe, J. G. (2004). Functional, molecular and pharmacological advances in 5-HT<sub>7</sub> receptor research. *Trends Pharmacol. Sci.* 25, 481–486. doi: 10.1016/j.tips.2004.07.002
- Henze, D. A., and Buzsáki, G. (2001). Action potential threshold of hippocampal pyramidal cells *in vivo* is increased by recent spiking activity. *Neuroscience* 105, 121–130. doi: 10.1016/s0306-4522(01)00167-1
- Hernandez-Lopez, S., Garduño, J., and Mihailescu, S. (2013). Nicotinic modulation of serotonergic activity in the dorsal raphe nucleus. *Rev. Neurosci.* 24, 455–469. doi: 10.1515/revneuro-2013-0012
- Hoyer, D., Hannon, J. P., and Martin, G. R. (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol. Biochem. Behav.* 71, 533–554. doi: 10.1016/s0091-3057(01)00746-8
- Jackson, J., Bland, B. H., and Antle, M. C. (2009). Nonserotonergic projection neurons in the midbrain raphe nuclei contain the vesicular glutamate transporter VGLUT3. *Synapse* 63, 31–41. doi: 10.1002/syn.20581
- Kirby, L. G., Pernar, L., Valentino, R. J., and Beck, S. G. (2003). Distinguishing characteristics of serotonin and non-serotonin-containing cells in the dorsal raphe nucleus: electrophysiological and immunohistochemical studies. *Neuroscience* 116, 669–683. doi: 10.1016/s0306-4522(02)00584-5
- Liu, R., Jolas, T., and Aghajanian, G. (2000). Serotonin 5-HT<sub>2</sub> receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. *Brain Res.* 873, 34–45. doi: 10.1016/s0006-8993(00)02468-9
- McDevitt, R. A., and Neumaier, J. F. (2011). Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. *J. Chem. Neuroanat.* 41, 234–246. doi: 10.1016/j.jchemneu.2011.05.001
- Mnie-Filali, O., Faure, C., Lambás-Señas, L., El Mansari, M., Belblidia, H., Gondard, E., et al. (2011). Pharmacological blockade of 5-HT<sub>7</sub> receptors as a putative fast acting antidepressant strategy. *Neuropsychopharmacology* 36, 1275–1288. doi: 10.1038/npp.2011.13
- Munday, M. K., Fletcher, A., and Marsden, C. A. (1996). Effects of 8-OHDPAT and 5-HT<sub>1A</sub> antagonists WAY100135 and WAY100635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing. *Br. J. Pharmacol.* 117, 750–756. doi: 10.1111/j.1476-5381.1996.tb15254.x
- Nikiforuk, A. (2015). Targeting the serotonin 5-HT<sub>7</sub> receptor in the search for treatments for CNS disorders: rationale and progress to date. *CNS Drugs* 29, 265–275. doi: 10.1007/s40263-015-0236-0
- Paul, E. D., and Lowry, C. A. (2013). Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders. *J. Psychopharmacol.* 27, 1090–1106. doi: 10.1177/0269881113490328
- Paxinos, G., and Watson, C. (1998). *The Rat Brain in Stereotaxic Coordinates*. San Diego: Academic Press.
- Penington, N. J., Kelly, J. S., and Fox, A. P. (1991). A study of the mechanism of Ca<sup>2+</sup> current inhibition produced by serotonin in rat dorsal raphe neurons. *J. Neurosci.* 11, 3594–3609.
- Roberts, C., Allen, L., Langmead, C. J., Hagan, J. J., Middlemiss, D. N., and Price, G. W. (2001). The effect of SB-269970, a 5-HT<sub>7</sub> receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. *Br. J. Pharmacol.* 132, 1574–1580. doi: 10.1038/sj.bjp.0703979
- Shikanai, H., Yoshida, T., Konno, K., Yamasaki, M., Izumi, T., Ohmura, Y., et al. (2012). Distinct neurochemical and functional properties of GAD67-containing 5-HT neurons in the rat dorsal raphe nucleus. *J. Neurosci.* 32, 14415–14426. doi: 10.1523/JNEUROSCI.5929-11.2012
- Soiza-Reilly, M., and Commons, K. G. (2011). Glutamatergic drive of the dorsal raphe nucleus. *J. Chem. Neuroanat.* 41, 247–255. doi: 10.1016/j.jchemneu.2011.04.004
- Soiza-Reilly, M., and Commons, K. G. (2014). Unraveling the architecture of the dorsal raphe synaptic neuropil using high-resolution neuroanatomy. *Front. Neural Circuits* 8:105. doi: 10.3389/fncir.2014.00105
- Tokarski, K., Bobula, B., Grzegorzewska-Hiczwa, M., Kusek, M., and Hess, G. (2012). Stress- and antidepressant treatment-induced modifications of 5-HT<sub>7</sub> receptor functions in the rat brain. *Pharmacol. Rep.* 64, 1305–1315. doi: 10.1016/s1734-1140(12)70928-3
- Tokarski, K., Kusek, M., and Hess, G. (2011). 5-HT<sub>7</sub> receptors modulate GABAergic transmission in rat hippocampal CA1 area. *J. Physiol. Pharmacol.* 62, 535–540.
- Tokarski, K., Urban-Ciecko, J., Kossut, M., and Hess, G. (2007). Sensory learning-induced enhancement of inhibitory synaptic transmission in the barrel cortex of the mouse. *Eur. J. Neurosci.* 26, 134–141. doi: 10.1111/j.1460-9568.2007.05629.x
- Tokarski, K., Zahorodna, A., Bobula, B., and Hess, G. (2003). 5-HT<sub>7</sub> receptors increase the excitability of rat hippocampal CA1 pyramidal neurons. *Brain Res.* 993, 230–234. doi: 10.1016/j.brainres.2003.09.015
- Weissbourd, B., Ren, J., DeLoach, K. E., Guenther, C. J., Miyamichi, K., and Luo, L. (2014). Presynaptic partners of dorsal raphe serotonergic and GABAergic neurons. *Neuron* 83, 645–662. doi: 10.1016/j.neuron.2014.06.024
- Wesołowska, A., and Kowalska, M. (2008). Influence of serotonin 5-HT<sub>7</sub> receptor blockade on the behavioral and neurochemical effects of imipramine in rats. *Pharmacol. Rep.* 60, 464–474.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Kusek, Sowa, Kamińska, Golembiowska, Tokarski and Hess. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.